{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:15Z","timestamp":1762866975592},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NCI","award":["Genentech, Inc., a full member of the Roche Group","U10-CA-108068, U10-CA-180822, NCI-44066-26(AR); UG"],"award-info":[{"award-number":["Genentech, Inc., a full member of the Roche Group","U10-CA-108068, U10-CA-180822, NCI-44066-26(AR); UG"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1245\/s10434-016-5662-9","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T17:27:50Z","timestamp":1479490070000},"page":"1853-1860","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology\/NSABP Protocol B-40"],"prefix":"10.1245","volume":"24","author":[{"given":"Harry D.","family":"Bear","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Charles E.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine K.","family":"Zoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley M.","family":"Kidwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Robidoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Baez-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis M.","family":"Senecal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Margolese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soonmyung","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra M.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios P.","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"5662_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182\u20136.","journal-title":"N Engl J Med."},{"key":"5662_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3322\/canjclin.22.4.226","volume":"22","author":"AI Holleb","year":"1972","unstructured":"Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin. 1972;22:226\u20139.","journal-title":"CA Cancer J Clin."},{"key":"5662_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841\u20134.","journal-title":"Nature."},{"key":"5662_CR4","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593\u20139.","journal-title":"Cancer Res."},{"key":"5662_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2217\/fon.12.22","volume":"8","author":"CE Stevenson","year":"2012","unstructured":"Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol. 2012;8:403\u201314.","journal-title":"Future Oncol."},{"key":"5662_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ctrv.2014.05.006","volume":"40","author":"I K\u00fcmler","year":"2014","unstructured":"K\u00fcmler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev. 2014;40:960\u201373.","journal-title":"Cancer Treat Rev."},{"key":"5662_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11060-015-1868-0","volume":"124","author":"H Ladha","year":"2015","unstructured":"Ladha H, Pawar T, Gilbert MR, et al. Wound healing complications in brain tumor patients on bevacizumab. J Neurooncol. 2015;124:501\u20136.","journal-title":"J Neurooncol."},{"key":"5662_CR8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74:1891\u2013925.","journal-title":"Drugs."},{"key":"5662_CR9","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","volume":"21","author":"C Eveno","year":"2014","unstructured":"Eveno C, Passot G, Go\u00e9r\u00e9 D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21:1792\u2013800.","journal-title":"Ann Surg Oncol."},{"key":"5662_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/SAP.0b013e31824e5e57","volume":"71","author":"K Sharma","year":"2013","unstructured":"Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg. 2013;71:434\u201340.","journal-title":"Ann Plast Surg."},{"key":"5662_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clbc.2011.04.002","volume":"11","author":"DA Yardley","year":"2011","unstructured":"Yardley DA, Raefsky E, Castillo R, et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer. 2011;11:297\u2013305.","journal-title":"Clin Breast Cancer."},{"key":"5662_CR12","first-page":"4743","volume":"30","author":"M Koskas","year":"2010","unstructured":"Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, Dara\u00ef E. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer Res. 2010;30:4743\u20137.","journal-title":"Anticancer Res."},{"key":"5662_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jocn.2014.05.054","volume":"22","author":"DA Abrams","year":"2015","unstructured":"Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB Jr, Bota DA. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 2015;22:35\u20139.","journal-title":"J Clin Neurosci."},{"key":"5662_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","volume":"11","author":"D Bose","year":"2010","unstructured":"Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11:373\u201382.","journal-title":"Lancet Oncol."},{"key":"5662_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","volume":"62","author":"CR Gordon","year":"2009","unstructured":"Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62:707\u20139.","journal-title":"Ann Plast Surg."},{"key":"5662_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00384-011-1360-z","volume":"27","author":"HP Neeff","year":"2012","unstructured":"Neeff HP, Drognitz O, Klock A, et al. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis. 2012;27:635\u201345.","journal-title":"Int J Colorectal Dis."},{"key":"5662_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ejso.2011.06.004","volume":"37","author":"D Hompes","year":"2011","unstructured":"Hompes D, Ruers T. Review: incidence and clinical significance of bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol. 2011;37:737\u201346.","journal-title":"Eur J Surg Oncol."},{"key":"5662_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00268-009-0251-8","volume":"34","author":"M Mahfud","year":"2010","unstructured":"Mahfud M, Breitenstein S, El-Badry AM, et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg. 2010;34:92\u2013100.","journal-title":"World J Surg."},{"key":"5662_CR19","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1200\/JCO.2008.17.7857","volume":"26","author":"SB Kesmodel","year":"2008","unstructured":"Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26:5254\u201360.","journal-title":"J Clin Oncol."},{"key":"5662_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11060-014-1482-6","volume":"119","author":"AR Golas","year":"2014","unstructured":"Golas AR, Boyko T, Schwartz TH, Stieg PE, Boockvar JA, Spector JA. Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin\u00ae) and radiation. J Neurooncol. 2014;119:327\u201331.","journal-title":"J Neurooncol."},{"key":"5662_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/CAD.0b013e328349c7bb","volume":"22","author":"I Kriegel","year":"2011","unstructured":"Kriegel I, Cottu PH, Fourchotte V, et al. Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy. Anticancer Drugs. 2011;22:1020\u20133.","journal-title":"Anticancer Drugs."},{"key":"5662_CR22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/cncr.25573","volume":"117","author":"JP Erinjeri","year":"2011","unstructured":"Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117:1296\u2013301.","journal-title":"Cancer."},{"key":"5662_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ejca.2011.11.021","volume":"48","author":"J Cort\u00e9s","year":"2012","unstructured":"Cort\u00e9s\u00a0J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer. 2012;48:475\u201381.","journal-title":"Eur J Cancer."},{"key":"5662_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1245\/s10434-010-1366-8","volume":"18","author":"M Golshan","year":"2011","unstructured":"Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011;18:733\u20137.","journal-title":"Ann Surg Oncol."},{"key":"5662_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-013-2682-z","volume":"141","author":"KJ Kansal","year":"2013","unstructured":"Kansal KJ, Dominici LS, Tolaney et al. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. Breast Cancer Res Treat. 2013;141:255\u20139.","journal-title":"Breast Cancer Res Treat."},{"key":"5662_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa1111097","volume":"366","author":"HD Bear","year":"2012","unstructured":"Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310\u201320.","journal-title":"N Engl J Med."},{"key":"5662_CR27","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1016\/S1470-2045(15)00041-8","volume":"16","author":"HD Bear","year":"2015","unstructured":"Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1037\u201348. Erratum in: Lancet Oncol. 2015;16:e589.","journal-title":"Lancet Oncol."},{"key":"5662_CR28","doi-asserted-by":"crossref","unstructured":"Agresti A. (2002). Categorical Data Analysis (second ed). Wiley . https:\/\/mathdept.iut.ac.ir\/sites\/mathdept.iut.ac.ir\/files\/AGRESTI.PDF. Accessed 8 Aug 2016.","DOI":"10.1002\/0471249688"},{"key":"5662_CR29","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Di\u00e9ras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without Bev for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252\u201360.","journal-title":"J Clin Oncol."},{"key":"5662_CR30","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239\u201347.","journal-title":"J Clin Oncol."},{"key":"5662_CR31","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376.","journal-title":"N Engl J Med."},{"key":"5662_CR32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/jco.2014.32.15_suppl.500","volume":"32","author":"K Miller","year":"2014","unstructured":"Miller K, O\u2019Neill AM, Dang CT, et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol. 2014;32:500.","journal-title":"J Clin Oncol."},{"key":"5662_CR33","doi-asserted-by":"publisher","first-page":"S01","DOI":"10.1158\/0008-5472.SABCS13-S1-03","volume":"73","author":"DJ Slamon","year":"2013","unstructured":"Slamon DJ, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab \u00b1 bevacizumab in patients with HER2-positive, node positive or high risk node-negative breast cancer. Cancer Res. 2013;73:S01\u201303.","journal-title":"Cancer Res."},{"key":"5662_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","volume":"14","author":"D Cameron","year":"2013","unstructured":"Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933\u201342.","journal-title":"Lancet Oncol."},{"key":"5662_CR35","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","volume":"24","author":"B Gerber","year":"2013","unstructured":"Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers. Results from the Geparquinto study (GBG44). Ann Oncol. 2013;24:2978\u201384.","journal-title":"Ann Oncol."},{"key":"5662_CR36","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/annonc\/mdu455","volume":"25","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Loibl S, Untch M, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44\u2014GeparQuinto). Ann Oncol. 2014;25:2363\u201372.","journal-title":"Ann Oncol."},{"key":"5662_CR37","doi-asserted-by":"crossref","unstructured":"Sikov W, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC \u00b1 carboplatin and\/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Abstr S2\u201305; SABCS. 2015.","DOI":"10.1158\/1538-7445.SABCS15-S2-05"},{"key":"5662_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-016-3889-6","volume":"158","author":"ZA Nahleh","year":"2016","unstructured":"Nahleh, ZA, Barlow, WE, Hayes, DF, et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rated in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016;158:485\u201395.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-016-5662-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:37:53Z","timestamp":1628609873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-016-5662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["5662"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5662-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]},"assertion":[{"value":"1 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}